Advice
following a full submission:
apixaban (Eliquis®) is accepted for use within NHS Scotland.
Indication under review: Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery.
In two large phase III double-blind comparative studies, in patients undergoing elective hip or knee replacement surgery, apixaban was superior to a low molecular weight heparin for the incidence of VTE and all cause death whilst incidence of major bleeding events was similar between groups.
Download detailed advice141KB (PDF)
Medicine details
- Medicine name:
- apixaban (Eliquis)
- SMC ID:
- 741/11
- Indication:
- For the treatment of venous thromboembolic events (VTE) in adult patients who have undergone elective hip (THR) or knee (TKR) replacement surgery.
- Pharmaceutical company
- Bristol-Myers Squibb Pharmaceuticals Ltd
- BNF chapter
- Cardiovascular system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 12 December 2011